1 Studies have been carried out to investigate the disposition of nicardipine hydrochloride following intravenous and oral administration to male volunteers. 2 Following oral administration of a radiolabelled dose, nicardipine was shown to be rapidly and extensively metabolised and to be rapidly eliminated from plasma. 3 After intravenous infusion of nicardipine at 5 mg-' for 3 h, plasma levels declined biexponentially, and clearance values were of the same order as hepatic blood flow. 4 With repeated oral administration, 20 mg three times daily for 28 days, plasma levels rose over the first 3 days of administration and then declined to some extent. Possible reasons for this decline are discussed. 5 Steady-state plasma levels and bioavailability show a nonlinear relationship with doses over the range 10-40 mg three times daily. 6 Food consumption has been shown to reduce the bioavailability of nicardipine when the food is taken before or at the same time as nicardipine administration.
Introduction
Nicardipine is a member of the class of dihydropyridine derivatives that have been shown to inhibit the intracellular migration of calcium ions. At present the drug is being evaluated in the therapy of hypertension, angina, and other cardiovascular indications.
The metabolism and pharmacokinetics of orally and intravenously administered nicardipine have been studied in animals. Following oral administration, nicardipine was rapidly absorbed, extensively metabolised, and rapidly eliminated (Higuchi et al., 1977 Higuchi & Shiobara, 1980) . Comparison with the intravenous findings showed that nicardipine was well absorbed but subject to extensive presystemic elimination. Nicardipine was metabolised predominantly in the liver (Higuchi & Shiobara, 1980 ) and the rate-limiting factor was blood supply to the liver.
The present studies were a continuation of those previously described , which were carried out to investigate the metabolism of nicardipine in man and to study the pharmacokinetics of nicardipine following oral and intravenous administration.
Methods

Subjects
The subjects were healthy, male volunteers from whom informed consent had been obtained before admission to the study. Further details of the individual studies are given in the Results Section. 14C in position 4 of the dihydropyridine ring ( Figure 1 ) and supplies of nicardipine and metabolites for use as chromatographic standards were provided by Syntex Research, Palo Alto.
Analysis of nicardipine Plasma levels of nicardipine were determined by gas chromatography (g.c.) (Higuchi et al., 1975) and high-performance liquid chromatography (h.p.l.c.) (Wu et al., 1984) . Using g.c., nicardipine was quantified following oxidation to a pyridine analogue metabolite (M5). It is thought that the ratio of the plasma levels of this metabolite ( Figure 1) Gibaldi & Perrier (1975) :
where C Plasma concentration (ng ml-'),
Ro Infusion rate (mg h-'), Investigation of the metabolites in urine showed that there were two main classes of metabolites: those where the dihydropyridine ring was intact and those where oxidation had occurred resulting in the pyridine analogue metabolite (Figure 1 ). Several metabolites were identified where sequential metabolism of the N-benzyl side chain had occurred.
The probable metabolic pathway ofnicardipine is shown in Figure 2 . shows plasma levels at each dose in one volunteer, while the relationship between bioavailability and dose is shown in Figure 7 .
Effect offood on bioavailability
The effect of food on the bioavailability of nicardipine was investigated in a blind cross-over study where healthy, male volunteers received nicardipine 20 mg 1 h before, during or 1 h after a standard meal. In each of the three study phases, volunteers received nicardipine 20 mg three times daily for 3 days prior to the study. Mean plasma profiles following nicardipine administration before and after the standard meal are shown in Figure 8 . 
Discussion
The studies presented in this paper show that the metabolism of nicardipine in man is rapid and extensive, as had been predicted by the animal studies. It is likely that the liver is the major eliminating organ, and it is clear that, although no nicardipine is excreted unchanged in the urine, the kidney plays a role in the excretion of a large proportion of any administered dose. The major products, at least in urine, are conjugates of the alcohol metabolites.
Investigation of the bioavailability of an oral dose shows that there is a dose dependency. The moderately low bioavailability is the result of presystemic elimination, not of poor absorption. It is likely that the dose-dependent bioavailability is due to increasing saturation of the presystemic elimination processes. From the studies carried out so far, there has been no indication of dose dependency in elimination kinetics.
The terminal elimination rates appear to differ following different oral doses, and the elimination rate following the intravenous infusion is of the same order as that seen with the low oral doses. The simplest explanation of this is that the analytical method is not adequately sensitive to detect and quantitate late elimination phases where the dose is low or the duration of dosing is short.
The changes seen in AUC on repeated oral administration of nicardipine show an initial increase, which is probably related to saturation and to equilibration of presystemic elimination processes. However, the subsequent decrease is less easily explained, and its exact mechanism remains to be elucidated. It has been shown that nicardipine does not alter the indices of hiepaticdrug-metabolising enzyme status , so it is unlikely that nicardipine is inducing its own metabolism. By altering blood flow patterns through a pharmacological action, nicardipine may alter either its clearance (which is blood-flow limited) or its bioavailability (by changing blood flow during the absorption phase).
The presence of food in the gastrointestinal tract during the absorption phase of nicardipine appears to reduce its bioavailability and to delay the achievement of peak plasma levels of nicardipine. A reduction in the rate of absorption may decrease portal blood concentrations. As a result, the fraction of the dose eliminated during the first-pass will increase because of the nonlinear nature of the absorption kinetics of nicardipine.
Thus in conclusion, in common with other dihydropyridine compounds, nicardipine has been found to be rapidly and extensively metabolised, with both its metabolism and pharmacokinetics under hepatic control. Saturable presystemic elimination processes result in nonlinear kinetics and explain the effects of food on nicardipine bioavailability.
